⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11213274 | 0.82 | — | — | |
| SCHEMBL11347827 | 0.82 | GABBR2 (0.68) | — | |
| SCHEMBL11287065 | 0.82 | GABBR2 (0.68) | — | |
| SCHEMBL11319722 | 0.79 | GABBR2 (0.65) | — | |
| Methyl Phosphonate SCHEMBL7997367 | 0.79 | GABBR2 (0.65) | — | |
| SCHEMBL603589 | 0.79 | GABBR2 (0.65) | — | |
| SCHEMBL10952612 | 0.77 | — | — | |
| Methyl Phosphonate SCHEMBL7997370 | 0.77 | GABBR2 (0.62) | — | |
| SCHEMBL35883 | 0.77 | — | — | |
| Methyl Phosphonate SCHEMBL8007050 | 0.77 | GABBR2 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228772-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2025-07-17 | — | — | US | claimed |
| EP-4536194-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | EsoCap AG (CH) | 2025-04-16 | — | — | EP | claimed |
| CN-119317428-A | Drug delivery system comprising reflux inhibitors for application to esophageal mucosa | 伊斯凯普公司 | 2025-01-14 | — | — | CN | claimed |
| US-20240390311-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-28 | — | — | US | claimed |
| EP-4405049-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | The Regents of the University of California (US) | 2024-07-31 | — | — | EP | claimed |
| WO-2023237426-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2023-12-14 | — | — | WO | claimed |
| US-20230381125-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-30 | — | — | US | claimed |
| EP-4217002-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | The Regents of the University of California (US) | 2023-08-02 | — | — | EP | claimed |
| WO-2023101899-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING SJOGREN'S SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-08 | — | — | WO | claimed |
| WO-2023048781-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-30 | — | — | WO | claimed |
| EP-1202727-A1 | USE OF AGONISTS OF GABAB RECEPTORS AND PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, IN THE THERAPY OF MAINTAINING NICOTINE ABSTINENCE IN NICOTINE-DEPENDENT PATIENTS | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO S.P.A (IT) | 2002-05-08 | — | — | EP | claimed |
| WO-2001008675-A1 | USE OF AGONISTS OF GABAB RECEPTORS AND PHARMACEUTICALLY ACCEPTABLE DERIVATES THEREOF, IN THE THERAPY OF MAINTAINING NICOTINE ABSTINENCE-DEPENDENT PATIENTS | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO S.P.A. (IT) | 2001-02-08 | — | — | WO | claimed |
| US-6117908-A | Use of GABAB receptor agonists as reflux inhibitors | ASTRA AKTIEBOLAG (SE) | 2000-09-12 | — | — | US | claimed |
| EP-0936906-A1 | REFLUX INHIBITORS | Astra Aktiebolag (SE) | 1999-08-25 | — | — | EP | claimed |
| WO-1998011885-A1 | REFLUX INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-03-26 | — | — | WO | claimed |
| US-5567840-A | AS 4-AMINOBUTYRIC ACID AGONIST; MUSCLE RELAXANTS | CIBA-GEIGY CORPORATION (US) | 1996-10-22 | — | — | US | claimed |
| WO-1996011680-A2 | USE OF GABA AGONISTS IN THE TREATMENT OF EMESIS | GLAXO GROUP LIMITED (GB) | 1996-04-25 | — | — | WO | claimed |
| EP-0399949-B1 | Substituted aminoalkylphosphinic acids | CIBA GEIGY AG (CH) | 1995-04-12 | — | — | EP | claimed |
| US-5281747-A | Pharmaceuticals | CIBA-GEIGY CORPORATION (US) | 1994-01-25 | — | — | US | claimed |
| EP-0399949-A1 | Substituted aminoalkylphosphinic acids | CIBA-GEIGY AG (CH) | 1990-11-28 | — | — | EP | claimed |